SAN FRANCISCO, CA -- (Marketwire) -- 11/13/12 -- CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on genomics, today announced that it is scheduled to present at the National Investment Banking Association (NIBA) Conference November 14-16, 2012, at The Venetian Resort Hotel-Casino in Las Vegas.
CollabRx Chairman and Co-CEO Thomas R. Mika will be presenting to investors and available for one-on-one meetings throughout the conference.
CollabRx uses cloud-based expert systems to inform healthcare decision-making by aggregating and contextualizing the world's knowledge on molecular medicine with specific insights from the nation's top clinical experts. The company combines proprietary content and technology to provide clinically relevant and dynamically updated knowledge on clinical trials, drugs, biologics and other information relevant for cancer treatment planning. This knowledge is supported by CollabRx's large and growing network of over 50 leading clinical practitioners in the United States. While CollabRx and its advisors do not provide specific treatment recommendations, this clinically relevant knowledge is a key part of the "context engine" for informing healthcare decision-making.
National Investment Banking Association is a national trade association of national, regional and independent broker dealers, investment banking firms, investment advisor companies, and related capital market service providers. Since its inception, NIBA member firms have successfully completed over 1,000 equity offerings totaling approximately $10 billion in new capital for America's finest emerging growth companies. The member firms of NIBA represent over 8,000 registered representatives with an estimated $78 billion in assets under management, and are responsible for 90% of all initial public offerings under $20 million. For more information, please visit: www.nibanet.org.
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
James M. Karis
Thomas R. Mika
Robert Ferri Partners, LLC
(415) 575-1589 (direct)